Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry:Results from the Dutch Castration-resistant Prostate Cancer Registry

BACKGROUND: Cross resistance between androgen-receptor targeting therapies (ARTs) (abiraterone acetate plus prednisone [ABI+P] or enzalutamide [ENZ]) for treatment of metastatic castration-resistant prostate cancer (mCRPC) may affect responses to second ART (ART2). OBJECTIVE: To establish treatment duration and prostate-specific antigen (PSA) response of ART2 in real-world mCRPC patients treated with or without other life-prolonging drugs (LPDs; ie, docetaxel, cabazitaxel, or radium-223) between ART1 and ART2. DESIGN, SETTING, AND PARTICIPANTS: Castration-resistant prostate cancer patients, di... Mehr ...

Verfasser: Kuppen, Malou C.P.
Westgeest, Hans M.
van den Eertwegh, Alphonsus J.M.
van Moorselaar, Reindert J.A.
van Oort, Inge M.
Coenen, Juleon L.L.M.
van den Bergh, A. C.M.Fons
Mehra, Niven
Somford, Diederik M.
Bergman, Andre M.
Ten Bokkel Huinink, Daan
Fossion, Laurent
Geenen, Maud M.
Hendriks, Mathijs P.
van de Luijtgaarden, Addy C.M.
Polee, Marco B.
Weijl, Nir I.
van de Wouw, Agnes J.
de Wit, Ronald
Uyl-de Groot, Carin A.
Gerritsen, Winald R.
Dokumenttyp: Artikel
Erscheinungsdatum: 2021
Reihe/Periodikum: Kuppen , M C P , Westgeest , H M , van den Eertwegh , A J M , van Moorselaar , R J A , van Oort , I M , Coenen , J L L M , van den Bergh , A C M F , Mehra , N , Somford , D M , Bergman , A M , Ten Bokkel Huinink , D , Fossion , L , Geenen , M M , Hendriks , M P , van de Luijtgaarden , A C M , Polee , M B , Weijl , N I , van de Wouw , A J , de Wit , R , Uyl-de Groot , C A & Gerritsen , W R 2021 , ' Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry : Results from the Dutch Castration-resistant Prostate Cancer Registry ' , European urology oncology , vol. 4 , pp. 618-627 . https://doi.org/10.1016/j.euo.2019.09.005
Schlagwörter: /dk/atira/pure/keywords/researchprograms/AFL000800/EMCNIHES056302 / name=EMC NIHES-05-63-02 Quality / /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being / name=SDG 3 - Good Health and Well-being
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29042467
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://pure.eur.nl/en/publications/48f6d2d4-c72c-4415-9744-e5a66d584868

BACKGROUND: Cross resistance between androgen-receptor targeting therapies (ARTs) (abiraterone acetate plus prednisone [ABI+P] or enzalutamide [ENZ]) for treatment of metastatic castration-resistant prostate cancer (mCRPC) may affect responses to second ART (ART2). OBJECTIVE: To establish treatment duration and prostate-specific antigen (PSA) response of ART2 in real-world mCRPC patients treated with or without other life-prolonging drugs (LPDs; ie, docetaxel, cabazitaxel, or radium-223) between ART1 and ART2. DESIGN, SETTING, AND PARTICIPANTS: Castration-resistant prostate cancer patients, diagnosed between 2010 and 2016 were retrospectively registered in Castration-resistant Prostate Cancer Registry (CAPRI). Patients treated with both ARTs were clustered into two subgroups: ART1>ART2 or ART1>LPD>ART2. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Outcomes were ≥50% PSA response and treatment duration of ART2. Descriptive statistics and binary logistic regression after multiple imputations were performed. RESULTS AND LIMITATIONS: A total of 273 patients were included with a median follow-up of 8.4 mo from ART2. Patients with ART1>ART2 were older and had favourable prognostic characteristics at ART2 baseline compared with patients with ART1>LPD>ART2. No differences between ART1>ART2 and ART1>LPD>ART2 were found in PSA response and treatment duration. Multivariate analysis suggested that PSA response of ART2 was less likely in patients with visceral metastases (odds ratio [OR] 0.143, p=0.04) and more likely in patients with a relatively longer duration of androgen-deprivation treatment (OR 1.028, p=0.01) and with ABI + P before ENZ (OR 3.192, p=0.02). A major limitation of this study was missing data, a common problem in retrospective observational research. CONCLUSIONS: The effect of ART2 seems to be low, with a low PSA response rate and a short treatment duration irrespective of interposed chemotherapy or radium-223, especially in patients with short time on castration, visceral ...